Rev Bras Ginecol Obstet 2016; 38(11): 564-575
DOI: 10.1055/s-0036-1594289
Review Article
Thieme Publicações Ltda Rio de Janeiro, Brazil

The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis

Eficácia da terapia anticolinérgica na bexiga hiperativa: revisão sistemática e metanálise
Andrea Moura Rodrigues Maciel da Fonseca
1   Urogynecology Division, Gynecology Discipline, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
Mariana Furtado Meinberg
1   Urogynecology Division, Gynecology Discipline, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
Marilene Vale de Castro Monteiro
1   Urogynecology Division, Gynecology Discipline, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
Matheus Roque
1   Urogynecology Division, Gynecology Discipline, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
Jorge Milhen Haddad
2   Urogynecology Division, Gynecology Discipline, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
Rodrigo Aquino Castro
3   Urogynecology Division, Gynecology Discipline, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
› Author Affiliations
Further Information

Publication History

27 November 2015

30 September 2016

Publication Date:
22 December 2016 (online)


The overactive bladder (OAB) has a significant negative impact on the quality of life of patients. Antimuscarinics have become the pharmacological treatment of choice for this condition. The objective of this systematic review and meta-analysis is to examine the evidence from randomized clinical trials about the outcomes of the antimuscarinic drugs available in Brazil on OABs. We searched MEDLINE and the Cochrane Central Register of Controlled Trials from the inception of these databases through to September 2015. The primary outcome measures were the mean decrease in urge urinary incontinence episodes and the mean decrease in the frequency of micturition. The results suggest that there is a moderate to high amount of evidence supporting the benefit of using anticholinergic drugs in alleviating OAB symptoms when compared with placebo. It is still not clear whether any of the specific drugs that are available in Brazil offer advantages over the others. These drugs are associated with adverse effects (dry mouth and constipation), although they are not related to an increase in the number of withdrawals.


A bexiga hiperativa determina um impacto negativo na qualidade de vida dos nossos pacientes. Os antimuscarínicos tornaram-se o tratamento farmacológico de escolha para essa condição. O objetivo desta revisão sistemática e metanálise é examinar as melhores evidências científicas sobre estas medicações disponíveis no Brasil no tratamento de mulheres com bexiga hiperativa. As bases de dados utilizadas foram MEDLINE e a biblioteca da Cochrane, das quais selecionamos os ensaios clínicos randomizados até setembro de 2015. Os principais desfechos analisados foram a diminuição dos episódios de incontinência urinária de urgência e a diminuição da frequência de micção. Os resultados sugerem que as drogas existentes no Brasil sustentam o benefício dos anticolinérgicos no alívio dos sintomas da bexiga hiperativa quando comparadas com o placebo. Em termos de eficácia, as medicações apresentam resultados semelhantes no controle dos sintomas. Essas drogas estão associadas a efeitos adversos importantes, tais como boca seca e constipação, e esses efeitos adversos não influenciaram no uso da medicação.

  • References

  • 1 Haylen BT, de Ridder D, Freeman RM , et al; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29 (1) 4-20
  • 2 Irwin DE, Milsom I, Hunskaar S , et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6) 1306-1314 , discussion 1314–1315
  • 3 Stewart WF, Van Rooyen JB, Cundiff GW , et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6) 327-336
  • 4 Townsend MK, Minassian VA, Okereke OI, Resnick NM, Grodstein F. Urinary incontinence and prevalence of high depressive symptoms in older black versus white women. Int Urogynecol J Pelvic Floor Dysfunct 2014; 25 (6) 823-829
  • 5 Sexton CC, Notte SM, Maroulis C , et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65 (5) 567-585
  • 6 Moroni RM, Magnani PS, Haddad JM, Castro RdeA, Brito LG. Conservative treatment of stress urinary incontinence: a systematic review with meta-analysis of randomized controlled trials. Rev Bras Ginecol Obstet 2016; 38 (2) 97-111
  • 7 Gormley EA, Lightner DJ, Burgio KL , et al; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188 (6, Suppl) 2455-2463
  • 8 Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother 2016; 17 (10) 1317-1325
  • 9 Brown ET, Martin L, Dmochowski RR. New evidence in the treatment of overactive bladder. Curr Opin Obstet Gynecol 2015; 27 (5) 366-372
  • 10 Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20 (4) 470-475
  • 11 Juliato CR, Santos Júnior LC, Haddad JM, Castro RA, Lima M, Castro EB. Mesh surgery for anterior vaginal wall prolapse: a meta-analysis. Rev Bras Ginecol Obstet 2016; 38 (7) 356-364
  • 12 Moher D, Liberati A, Tetzlaff J, Altman DG ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
  • 13 Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. London: The Cochrane Colaboration; 2011
  • 14 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
  • 15 Appell RA, Sand P, Dmochowski R , et al; Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76 (4) 358-363
  • 16 Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10 (5) 283-289
  • 17 Lee JG, Hong JY, Choo MS , et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 2002; 9 (5) 247-252
  • 18 Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165 (5) 1452-1456
  • 19 Chapple CR, Rechberger T, Al-Shukri S , et al; YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93 (3) 303-310
  • 20 Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 2001; 98 (1) 97-102
  • 21 Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004; 64 (2) 269-274 , discussion 274–275
  • 22 Millard R, Tuttle J, Moore K , et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161 (5) 1551-1555
  • 23 Swift S, Garely A, Dimpfl T, Payne C ; Tolterodine Study Group. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14 (1) 50-54 , discussion 54–55
  • 24 Van Kerrebroeck PE, Amarenco G, Thüroff JW , et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17 (5) 499-512
  • 25 Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A ; Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57 (3) 414-421
  • 26 Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50 (5) 799-807
  • 27 Cardozo L, Hessdörfer E, Milani R , et al; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102 (9) 1120-1127
  • 28 Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73 (1) 14-18
  • 29 But I, Goldstajn MS, Oresković S. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study. Coll Antropol 2012; 36 (4) 1347-1353
  • 30 Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol 2007; 39 (4) 1069-1077
  • 31 Barkin J, Corcos J, Radomski S , et al; UROMAX Study Group. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004; 26 (7) 1026-1036
  • 32 Leung HY, Yip SK, Cheon C , et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 2002; 90 (4) 375-380
  • 33 Jonas U, Höfner K, Madersbacher H, Holmdahl TH ; The International Study Group. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15 (2) 144-151
  • 34 Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013; 64 (1) 74-81
  • 35 Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int 2008; 102 (2) 208-213
  • 36 Diokno AC, Appell RA, Sand PK , et al; OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78 (6) 687-695
  • 37 Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. J Am Med Dir Assoc 2011; 12 (9) 639-647
  • 38 Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15 (4) 243-248
  • 39 Versi E, Appell R, Mobley D, Patton W, Saltzstein D ; The Ditropan XL Study Group. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95 (5) 718-721
  • 40 Yoo DS, Han JY, Lee KS, Choo MS. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. Int J Clin Pract 2012; 66 (2) 132-138
  • 41 Chapple CR, Fianu-Jonsson A, Indig M , et al; STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007; 52 (4) 1195-1203
  • 42 Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007; 51 (4) 1054-1064 , discussion 1064
  • 43 Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z ; 037 STUDY GROUP. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67 (4) 731-736, discussion 736
  • 44 Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998; 81 (1) 42-48
  • 45 Vardy MD, Mitcheson HD, Samuels TA , et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Int J Clin Pract 2009; 63 (12) 1702-1714
  • 46 Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45 (4) 420-429 , discussion 429
  • 47 Hill S, Khullar V, Wyndaele JJ, Lheritier K ; Darifenacin Study Group. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17 (3) 239-247
  • 48 Khullar V, Foote J, Seifu Y, Egermark M. Time-to-effect with darifenacin in overactive bladder: a pooled analysis. Int Urogynecol J Pelvic Floor Dysfunct 2011; 22 (12) 1573-1580
  • 49 Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005; 95 (4) 580-586
  • 50 Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005; 23 (4) 248-252
  • 51 Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006; 60 (1) 119-126
  • 52 Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002; 136 (5) 641-643
  • 53 Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002; 22 (3) 133-145
  • 54 Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann N Y Acad Sci 2000; 920: 315-320
  • 55 Culp DJ, Luo W, Richardson LA, Watson GE, Latchney LR. Both M1 and M3 receptors regulate exocrine secretion by mucous acini. Am J Physiol 1996; 271 (6 Pt 1): C1963-C1972
  • 56 Bymaster FP, Carter PA, Zhang L , et al. Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice. Life Sci 2001; 68 (22/23) 2473-2479
  • 57 Andersson KE. Potential benefits of muscarinic M3 receptor sensitivity. Eur Urol Suppl 2002; 1 (4) 23-28
  • 58 Gil DW, Krauss HA, Bogardus AM, WoldeMussie E. Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest Ophthalmol Vis Sci 1997; 38 (7) 1434-1442
  • 59 Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol 2001; 132 (4) 835-842
  • 60 Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother 2009; 10 (13) 2181-2194
  • 61 Karmarkar R, Khullar V. Emerging drugs for overactive bladder. Expert Opin Emerg Drugs 2015; 20 (4) 613-624
  • 62 Drake MJ, Chapple C, Esen AA , et al; BESIDE study investigators. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE). Eur Urol 2016; 70 (1) 136-145